US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Carlsmed, Inc. (CARL): Spinal Fusion Surgery Focused Company Looking to Be Next MedTech IPO Winner

Carlsmed Inc. (CARL): MedTech Makes Uninspiring Debut, Opens Flat and Trades Below Issue

Carlsmed, Inc. (CARL): Peeking at the Prospectus of the Next Medical Tech IPO

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Carlsmed is offering 6.7mm shares at $14.00-$16.00 equating to a market cap of $371m-$424m and is scheduled to debut on July 23rd</li>
<li>B Capital Group and U.S. Venture Partners have indicated an interest in purchasing up to approximately $20 million and $11 million, respectively.</li>
<li>MedTech companies like CarlsMed are easy to digest for IPO investors as the company typically sees sales in a strong trajectory going into the IPO.</li>
</ul>


Carlsmed is offering 6.7mm shares at $14.00-$16.00 equating to a market cap of $371m-$424m and is scheduled to debut on July 23rd
B Capital Group and U.S. Venture Partners have indicated an interest in purchasing up to approximately $20 million and $11 million, respectively.
MedTech companies like CarlsMed are easy to digest for IPO investors as the company typically sees sales in a strong trajectory going into the IPO.


Carlsmed, Inc. (CARL): MedTech Targeting the Spine Sets Terms for IPO